Skip to main navigation Skip to search Skip to main content

Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX-809 Alone in Combination with VX-770 in Subjects with Cystic Fibrosis

University at Buffalo

Project: Research

Project Details

StatusFinished
Effective start/end date12/14/10 → 12/31/14

Funding

  • Vertex Pharmaceuticals Incorporated: $101,271.36